CD8A and head and neck squamous cell carcinoma: While studies have demonstrated that higher presence of CD8+ cells correlate with a more favorable prognosis in both HNSCC and SCLC, there is only limited evidence that pre-treatment presence of CD8+ T-cells predicts response to checkpoint inhibitor therapy [15, 16].